3d agoGuruFocusBEARISH 32General
Archived explainer. For the current picture see today's HIMS page.
Why Is HIMS & HERS HEALTH I A (HIMS) Stock Down Today?
By the Top Tier Newswire AI Desk · November 11, 2026 at 12:02 AM ET · reviewed against 66 wire stories
HIMS & HERS HEALTH I A (HIMS) is down -16.61% in the latest session. Our newswire has captured 66 stories on HIMS across 20 sources in the last 36 hours, with AI sentiment reading bearish (avg 41/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Hims & Hers Health (HIMS) shares fell 16.61% to $19.13, driven by an expanded Federal Trade Commission complaint and a third-quarter earnings miss. The regulatory action added five states as co-plaintiffs, alleging deceptive privacy and billing practices.
What Happened
The FTC filed an amended complaint in the U.S. District Court for the Northern District of California on Tuesday. Arizona, Florida, Nebraska, Ohio, and Wisconsin joined the suit, which alleges the company shared patient health data with advertisers and engaged in misleading billing and cancellation practices. This regulatory development followed a Q3 report where revenue of $890.4 million missed estimates of $893 million, and EPS of -$0.14 missed the expected $0.06. The CFO noted that the company intentionally paced Q3 marketing spend on weight-loss products, while menopause therapies and testosterone testing boosted revenue per subscriber.
Jefferies maintained a Hold rating but lowered its price target to $24. Morgan Stanley also maintained an Equal-Weight rating, cutting its price target to $25. The company remains unprofitable with a trailing twelve-month EPS of -$0.62, though revenue grew 28.0% over the same period.
What The Data Shows
The stock has declined 30.9% over the last eight sessions, falling from $27.68 to $19.13. This move places the share price near the bottom of its 52-week range of $13.74 to $42.70. On November 10, 2026, the stock printed three fresh 52-week lows. Insider activity has been predominantly selling, with 14 sales totaling $6.0 million in the last 90 days and no buys. Recent Form 4 filings show General Counsel Soleil Boughton sold shares on October 14 and October 28, 2026, while CFO Oluyemi Okupe sold on October 1, 2026.
Options activity showed mixed sentiment with 31 notable prints in the last 36 hours. Call premium totaled $5.5 million compared to $3.4 million in put premium, with the largest single print at $809,000. The company has a beta of 2.50 and a market cap of $6.1 billion.
What To Watch
Investors will monitor the legal proceedings as the five new states pursue the amended complaint. The company’s ability to improve platform retention through its partnership with Eli Lilly will also be a key factor for future subscriber growth.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
HIMS by the numbers
Last: $19.13Session: -16.61%7 sessions: -17.55%Coverage: 66 stories / 20 sourcesAI sentiment: 41/100 (bearish)Mkt cap: $6.1B52w: $13.74 to $42.70
The headlines behind the move
3d agoGuruFocusBEARISH 34General
FTC Expands Complaint Against Hims & Hers Health (HIMS) Over Privacy and Billing Issues
3d agoStocktwits NewsBEARISH 34General
HIMS Stock Faces Dual Blow From Expanded FTC Privacy Lawsuit After Selloff Driven By Q3 Subscriber Loss
The Federal Trade Commission on Tuesday filed an amended complaint in the U.S. District Court for the Northern District of California, adding Arizona, Florida, Nebraska, Ohio, and Wisconsin as co-plaintiffs.
3d agoSeeking AlphaBEARISH 34General
Five more states join FTC privacy complaint against Hims & Hers Health
FTC adds five states to Hims & Hers complaint alleging patient health data sharing with advertisers and misleading billing and cancellation practices. Read more here.
3d agoThe FlyBEARISH 38General
Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 16.65%
3d agoThe FlyBEARISH 34General
States join FTC lawsuit alleging Hims & Hers engaged in ‘deceptive’ practices
3d agoFidelity NewsBEARISH 34Earnings
Sector Update: Healthcare Stocks Edge Higher Late Afternoon
Healthcare stocks edged higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF each increasing about 0.2%. The iShares Biotechnology ETF was falling 0.8%. In corporate news, Hims & Hers Health (HIMS.NaE) shares fell past 17% after the company reported a Q3 loss late Monday of $0.14 per diluted share, swinging from earnings of $0.06 a year earl...
3d agoSeeking AlphaBULLISH 63Earnings
Hims & Hers Health: Don't Nitpick Quarterly Results
Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. Read more on HIMS stock here.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on HIMS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier HIMS move explainers: 2026-11-11 · 2026-11-10 · 2026-11-09 · 2026-10-09 · 2026-09-30 · 2026-09-08 · 2026-08-28 · 2026-08-27 · 2026-08-26 · 2026-08-25 · 2026-08-24 · 2026-08-20 · 2026-08-19